Researchers found that liraglutide, the first long-acting GLP-1RAs, increased the expression of ACE2 in lungs and heart, which also raised a theoretical concern in patients with COVID-19 (Pal and Bhadada, 2020). Here, ACE2 is linked to COVID-19.